Based on the suggestion of IC activity in melanoma patients with NED, the BM-activity seen in our NBL study, and our preclinical murine data documenting better antitumor efficacy for smaller tumors (Figure 2) [39], we proposed that greater antitumor activity would be detected when using hu14.18-IL2 to treat patients with less “bulky” tumors. Here, IL2 is linked to melanoma.